Treatment adherence and adverse event management in chronic lymphocytic leukemia: challenges and strategies for the future

IF 3.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Expert Review of Clinical Pharmacology Pub Date : 2024-04-17 DOI:10.1080/17512433.2024.2344665

Maurlia D. Upchurch, Benyam Muluneh

引用次数: 0

Abstract

There has been a paradigm shift in the treatment of chronic lymphocytic leukemia (CLL) over the past decade. With the advent of self-administered targeted oral anticancer agents (OAAs), the treatme...

查看原文本刊更多论文

慢性淋巴细胞白血病的治疗依从性和不良事件管理：未来的挑战和战略

过去十年间，慢性淋巴细胞白血病（CLL）的治疗模式发生了转变。随着自给靶向口服抗癌药（OAAs）的出现，治疗慢性淋巴细胞白血病（CLL）的方法也发生了改变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Clinical Pharmacology PHARMACOLOGY & PHARMACY-

CiteScore

7.30

自引率

2.30%

发文量

127

期刊介绍： Advances in drug development technologies are yielding innovative new therapies, from potentially lifesaving medicines to lifestyle products. In recent years, however, the cost of developing new drugs has soared, and concerns over drug resistance and pharmacoeconomics have come to the fore. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery. Clinical Pharmacology provides an essential role in integrating the expertise of all of the specialists and players who are active in meeting such challenges in modern biomedical practice.